TY  - JOUR
A1  - Claessens, J.
A1  - Fuchsberger, A.
A1  - Günther, C.
A1  - Horn, G.
A1  - Howker, K.
A1  - Hulsebosch, R.J.
A1  - Mitchell, C.
A1  - Paterson, K.
A1  - Preneel, B.
A1  - Schellekens, D.
A1  - Schuba, Marko
T1  - Pioneering Advanced Mobile Privacy and Security
Y1  - 2003
N1  - electronic proceedings of the 18th IFIP International Information Security Conference, Athens, Greece, May 2003
SP  - 1
EP  - 17
ER  - 
TY  - JOUR
A1  - Hulsebosch, R. J.
A1  - Günther, C.
A1  - Horn, C.
A1  - Holtmanns, S.
A1  - Howker, K.
A1  - Paterson, K.
A1  - Claessens, J.
A1  - Schuba, Marko
ED  - Mitchell, Chris J.
T1  - Pioneering Advanced Mobile Privacy and Security
JF  - Security for mobility
Y1  - 2004
SN  - 9781849190886
U6  - https://doi.org/10.1049/PBTE051E_ch
N1  - IEE telecommunications series ; 51
SP  - 383
EP  - 432
PB  - Institution of Electrical Engineers
CY  - London
ER  - 
TY  - JOUR
A1  - Janz, Norbert
A1  - Ebling, Günther
A1  - Hipp, C.
A1  - Licht, Georg
T1  - Innovationsaktivitäten im Dienstleistungssektor: Ergebnis der Innovationserhebung 1997 / Ebling, G., C. Hipp, N. Janz, G. Licht und H. Niggemann
JF  - Innovationsaktivitäten in der deutschen Wirtschaft : Analyse der Mannheimer Innovationspanels im Verarbeitenden Gewerbe und im Dienstleistungssektor / Norbert Janz ... (Hrsg.)
Y1  - 1999
SN  - 3-7890-6179-4
N1  - ZEW-Wirtschaftsanalysen ; 41
SP  - 99
EP  - 222
PB  - Nomos-Verl.-Ges.
CY  - Baden-Baden
ER  - 
TY  - BOOK
A1  - Janz, Norbert
A1  - Ebling, Günther
A1  - Hipp, C.
A1  - Licht, Georg
T1  - Dienstleistungen in der Zukunft : Innovationsaktivitäten im Dienstleistungssektor ;  Befragung 1997 ; Kurzfassung / Janz, N., G. Ebling, C. Hipp, G. Licht und H. Niggemann
Y1  - 1998
PB  - ZEW Zentrum für Europäische Wirtschaftsförderung
CY  - Mannheim
ER  - 
TY  - BOOK
A1  - Janz, Norbert
A1  - Ebling, Günther
A1  - Hipp, C.
A1  - Licht, Georg
T1  - Innovationsaktivitäten im Dienstleistungssektor. Erhebung 1997 / Janz, N., G. Ebling, C. Hipp, G. Licht und H. Niggemann
Y1  - 1998
PB  - ZEW Zentrum für Europäische Wirtschaftsförderung
CY  - Mannheim
ER  - 
TY  - JOUR
A1  - Starke, Günther
A1  - Strunz, U.
A1  - Spieß, C.
T1  - Schweißprozeßparameteroptimierung mit Fuzzy-Logik
JF  - Schweißen und Schneiden. 47 (1995), H. 6
Y1  - 1995
SN  - 0036-7184
SP  - 494
EP  - 503
ER  - 
TY  - JOUR
A1  - Krebsbach, M.
A1  - Schiller, C.
A1  - Brunner, D.
A1  - Günther, G.
A1  - Hegglin, M. I.
A1  - Mottaghy, Darius
A1  - Riese, M.
A1  - Spelten, N.
A1  - Wernli, H.
T1  - Seasonal cycles and variability of O_3 and H_2O in the UT/LMS during SPURT
JF  - Atmospheric Chemistry and Physics
Y1  - 2006
U6  - https://doi.org/10.5194/acp-6-109-2006
VL  - 6
IS  - 1
SP  - 109
EP  - 125
ER  - 
TY  - JOUR
A1  - Scheer, Nico
A1  - Balimane, Praveen
A1  - Hayward, Michael D.
A1  - Buechel, Sandra
A1  - Kauselmann, Gunther
A1  - Wolf, C. Roland
T1  - Generation and Characterization of a Novel Multidrug Resistance Protein 2 Humanized Mouse Line
JF  - Drug Metabolism and Disposition
N2  - The multidrug resistance protein (MRP) 2 is predominantly expressed in liver, intestine, and kidney, where it plays an important role in the excretion of a range of drugs and their metabolites or endogenous compounds into bile, feces, and urine. Mrp knockout [Mrp2(−/−)] mice have been used recently to study the role of MRP2 in drug disposition. Here, we describe the first generation and initial characterization of a mouse line humanized for MRP2 (huMRP2), which is nulled for the mouse Mrp2 gene and expresses the human transporter in the organs and cell types where MRP2 is normally expressed. Analysis of the mRNA expression for selected cytochrome P450 and transporter genes revealed no major changes in huMRP2 mice compared with wild-type controls. We show that human MRP2 is able to compensate functionally for the loss of the mouse transporter as demonstrated by comparable bilirubin levels in the humanized mice and wild-type controls, in contrast to the hyperbilirubinemia phenotype that is observed in MRP2(−/−) mice. The huMRP2 mouse provides a model to study the role of the human transporter in drug disposition and in assessing the in vivo consequences of inhibiting this transporter by compounds interacting with human MRP2.
Y1  - 2012
U6  - https://doi.org/10.1124/dmd.112.047605
SN  - 1521-0111
VL  - 40
IS  - 11
SP  - 2212
EP  - 2218
PB  - ASPET
CY  - Bethesda, Md.
ER  -